Pulse Biosciences at Canaccord Genuity conference: nsPFA push gains pace

On 11 August 2026, Pulse Biosciences (PLSE) showcased its nanosecond pulsed field ablation (nsPFA) platform at Canaccord Genuity's 46th Annual Growth Conference. The company's stock has risen 202% year-to-date and is trading near its 52-week high of $45.90, reflecting growing enthusiasm from investors for its clinical progress. CEO Paul LaViolette emphasized atrial fibrillation and soft tissue ablation as key opportunities, but acknowledged the complexity of bringing a new energy technology to market. nsPFA is a next-generation platform that causes irreversible electroporation and regulated cell death without thermal damage, potentially enabling treatment in tight spaces near sensitive tissue.

The company's Nano-Pulse AF program and European feasibility study have shown promising results, with reduced ablation times and improved efficacy. Pulse Biosciences aims to obtain premarket approval (PMA) for atrial fibrillation and has already received 510(k) clearance for non-cardiac soft tissue ablation.